NEW YORK, Sept 29 – Chipmaker Ciphergen Biosystems (Nasdaq: CIPH) showed a gain of 100 percent on its first day of trading while bioinformatics company Genomica (Nasdaq: GNOM) gained only 2 percent.

Winton Gibbons, genomics analyst at William Blair, said, “Ciphergen’s strength reflects proteomics as being one of the important major investment areas in the post-genomic era. The fact that Genomica is relatively flat reflects that it’s difficult for a bioinformatics company to attract attention without proprietary content, even though its software is good.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.